FANG Liyuan, LI Huijie, WANG Zhipeng, et al. Research on Mechanism of Erxian Decoction in the Treatment of Breast Cancer Based on Network Pharmacology[J]. 2021,21(8):908-914.
FANG Liyuan, LI Huijie, WANG Zhipeng, et al. Research on Mechanism of Erxian Decoction in the Treatment of Breast Cancer Based on Network Pharmacology[J]. 2021,21(8):908-914. DOI: 10.14009/j.issn.1672-2124.2021.08.003.
基于网络药理学研究二仙汤治疗乳腺癌的作用机制
摘要
目的:利用网络药理学方法
探讨二仙汤治疗乳腺癌的潜在作用机制。方法:从中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform
OBJECTIVE: To probe into the potential mechanism of Erxian decoction in the treatment of breast cancer based on network pharmacology. METHODS: To collect the active components and effect targets of Erxian decoction through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform( TCMSP)
and establish a database of breast cancer target by GeneCards
OMIM and CTD database. The intersection targets of Erxian decoction acting on breast cancer were extract
the Cytoscape Version 3. 7. 1 software and STRING database were respectively adopted to draw the network diagram of “active components of Erxian decoction-effect targets-breast cancer” and protein-protein interaction( PPI)
Kyoto encyclopedia of genes and genomes( KEGG) pathway enrichment analysis and gene ontology( GO) function enrichment analysis were conducted by using R language-related software package
the effect intensity of active components and core targets was finally verified by molecular docking.RESULTS: Erxian decoction had 93 active components and 154 effect targets
breast cancer had 364 disease targets
there were 40 TCM component targets and breast cancer intersection targets
the herbal components with important effects were quercetin
kaempferol
isocorypalmine and β-sitosterol
and the key core targets were TP53
IL-6 and JUN. Totally 1 502 GO signaling pathways( P<0. 05) and 101 KEGG signaling pathways( P<0. 05) were screened out by GO functional enrichment analysis and KEGG pathway enrichment analysis
mainly involving the cancer pathways and PI3 K-AKT signaling pathway
etc. Results of the molecular docking showed a good binding between the compounds and effect targets. CONCLUSIONS: Erxian decoction has multi-component
multi-target and multi-pathway characteristics in the treatment of breast cancer
which can provide more support for follow-up studies.